Amitriptyline vs divalproate in migraine prophylaxis: A randomized controlled trial

Acta Neurologica Scandinavica

Volumn 128, Issue 1, 2013, Pages 65-72

  Kalita, J ^a   Bhoi, S K ^a   Misra, U K ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Amitriptyline; Antiepileptic; Divalproate; Migraine; Prophylaxis; randomized controlled trial; Sodium valproate; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; ANTIMIGRAINE AGENT; DIVALPROIC ACID; IBUPROFEN; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HAIR FALL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MIGRAINE; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL ANALOG SCALE; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AMITRIPTYLINE; ANALGESICS, NON-NARCOTIC; ANTICONVULSANTS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 84879181110     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12081     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention (CDC). Statistics: Prevalence of diabetes in the U.S. http://www.cdc.gov/diabetes/pubs/pdf/DiabetesReportCard.pdf (accessed 1 January 2013).
2. Centers for Disease Control and Prevention (CDC). Asthma prevalence, health care use, and mortality, 2000-2001; http://www.cdc.gov/nchs/products/ pibs/pubd/hestats/asthma/asthma.htm (accessed 1 April 2007).
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57.
4. World Health Organization (WHO). World Heath Report 2001. Mental health: new understanding, new hope. Geneva, Switzerland: WHO Library Cataloguing in Publication Data, 2001.
5. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45.
6. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002;58:885-94.
7. Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964;1:1236-9.
8. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-99.
9. Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51.
10. Dodick DW, Freitag F, Banks J et al. CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542-59.
11. Freitag FG, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9.
12. Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache 2001;41:271-8.
13. Mitsikostas DD, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: a randomized, double open, clinical trial. Funct Neurol 1997;12:267-76.
14. Bartolini M, Silvestrini M, Taffi R et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28:277-9.
15. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004;24:1-160.
16. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-4.
17. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994;44:647-51.
18. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F The effect of sodium valproate on chronic daily headache and its subgroups. J Headache Pain 2008;9:37-41.
19. Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6.
20. Kaniecki RG. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997;54:1141-5.
21. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-8.
22. Apostol G, Cady RK, Laforet GA et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 2008;48:1012-25.
23. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642-8.
24. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825-30.
25. Shahien R, Saleh SA, Bowirrat A. Intravenous sodium valproate aborts migraine headaches rapidly. Acta Neurol Scand 2011;123:257-65.
26. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002;22:491-512.
27. Rall TW, Schleifer LS. Drugs effective in the therapy of epilepsies. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 8th edn. New York: Pergamon Press, 1990;436-62.
28. van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia 2002;22:265-70.
29. Lake AE 3rd. Placebo, chronic daily headache, and pain: ten points to ponder. Curr Pain Headache Rep 2006;10:4-6.
30. Dodick DW, Turkel CC, DeGryse RE et al. on behalf of the PREEMPT Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36.